Acquisition of human concentrative nucleoside transporter 2 (hcnt2) activity by gene transfer confers sensitivity to fluoropyrimidine nucleosides in drug-resistant leukemia cells.
D001692:Biological Transport / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D018076:DNA, Complementary / Q000235:genetics; D019008:Drug Resistance, Neoplasm; D004354:Drug Screening Assays, Antitumor; D033721:Equilibrative Nucleoside Transporter 1; D005467:Floxuridine / Q000494:pharmacology*; D018014:Gene Transfer Techniques; D006219:Halogens / Q000737:chemistry; D006801:Humans; D020128:Inhibitory Concentration 50; D026901:Membrane Transport Proteins / Q000187:drug effects / Q000235:genetics / Q000378:metabolism*; D008969:Molecular Sequence Data; D011684:Purine Nucleosides / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D011741:Pyrimidine Nucleosides / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D012333:RNA, Messenger / Q000378:metabolism; D012964:Sodium / Q000378:metabolism; D013329:Structure-Activity Relationship; D014407:Tumor Cells, Cultured; D014529:Uridine / Q000031:analogs & derivatives* / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*